规范开展早产儿视网膜病变激光和抗血管内皮生长因子治疗  

Standardize the laser and anti-vascular endothelial growth factor treatment of retinopathy of prematurity

作　　者：张国明[1] 田汝银[1] Zhang Guoming;Tian Ruyin(Shenzhen Eye Hospital,Shenzhen Eye Hospital affiliated to Jinan University,Shenzhen Institute of Eye Disease Prevention and Control,Shenzhen 518040,China)

机构地区：[1]深圳市眼科医院、暨南大学附属深圳眼科医院、深圳市眼病防治研究所,深圳518040

出　　处：《中华眼科杂志》2023年第3期169-173,共5页Chinese Journal of Ophthalmology

基　　金：国家自然科学基金(82271103);广东省基础与应用基础研究基金(2022A1515012326)。

摘　　要：早产儿视网膜病变(ROP)是一类发生于早产、低出生体重儿的视网膜血管增生性疾病,是婴幼儿最常见的致盲和致低视力眼病。视网膜激光光凝仍是目前ROP治疗的金标准。近年来,玻璃体腔注射抗血管内皮生长因子(VEGF)药物的应用,为临床治疗ROP提供了新方法。但其治疗指征和治疗方法的把控仍存在诸多不当和偏差,导致抗VEGF药物在ROP治疗上的泛化和滥用现象。本文基于国内外ROP相关研究,对治疗指征、治疗方法进行归纳和客观评价,以期同道严控ROP治疗指征,科学、严谨地选择恰当的治疗方法,造福于患儿。Retinopathy of prematurity(ROP)is a retinal vascular proliferative disease occurring in premature and low birth weight infants,which is the leading cause of blindness and low vision in children.Laser photocoagulation is still recognized as the gold standard of treatment in ROP.Recently,anti-vascular endothelial growth factor(VEGF)therapy has become a novel alternative approach in clinical practice for ROP.However,there are still many improper and deviations in identifying indications and selecting therapeutic modalities,resulting in generalization and abuse of anti-VEGF drugs in treatment of ROP.The aim of this article is to summarize and objectively evaluate the treatment indications and methods of ROP based on related research at home and abroad,in order to strictly control the theraputic indications and scientifically and rigorously select appropriate therapeutic modalities for the benefit of children with ROP.

关 键 词：早产儿视网膜病 光凝固术 血管内皮生长因子A 

分 类 号：R779.63[医药卫生—眼科]